

WALLSTREETRESEARCH.ORG

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



Pressure BioSciences, Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

as of May 31, 2016

Pressure BioSciences, Inc. (OTCQB: PBIO) is a medical research products and technology company. PBI, based in South Easton, Massachusetts, serves academic and government laboratories, as well as biotechnology, pharmaceutical, and other life sciences companies. PBI develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. PBI has installed over 275 sample preparation systems in approximately 160 sites worldwide.

PBI recently signed an exclusive, two-year co-marketing agreement with a large strategic partner named SCIEX, which offers tremendous potential for revenue growth. SCIEX is a global leader in life sciences analytical technologies and a wholly-owned subsidiary of the Danaher Corporation (NYSE: DHR).

The PBI technology platform is based on constant (i.e., static) and alternating (i.e., Pressure Cycling Technology, or PCT) hydrostatic pressure; if used properly, pressure can help control the actions of molecules in biological samples, which can then have significant positive effects on scientific research studies. The Company offers products such as Barocycler Instruments, Shredder System and Consumables (PULSE and Micro Tubes). PBI holds 14 US and 10 foreign patents covering applications of PCT that offer significant advantages over competitive methods used to prepare samples for research evaluation.

The market for PBI consists of an estimated 500,000 scientists in over 80,000 research laboratories worldwide. PBI's development and sales efforts are in the biomarker discovery, drug discovery/design, and forensics areas. Potential customers could be expanded to areas such as: bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications. With these potential target areas, the growth potential for PBI is vast. The US medical device industry is expected to grow to \$133 Billion by 2016 (Source: selectusa. commerce.gov).

In April 2016, PBI completed an intensive, one-year project that called for the design and build of the initial working model ("breadboard") of the its new and improved Barocycler 2320EXTREME instrument. Designed initially for protein sample preparation prior to mass spectrometry analysis, including the SCIEX SWATH-MS ("PCT-SWATH"), the new PCT-based instrument can also be used in front of non-SCIEX mass specs, and in front of other instruments used for protein analysis.


PBI has recently come to an arrangement with a local ISO-certified contract manufacturer, and has given the manufacturer an initial order for 30 Barocycler 2320EXT units. The manufacture of the

initial four, commercial-grade units was completed on May 27, 2016.

PBI is poised for rapid growth during 2016 with the introduction of its new and enhanced products, buoyed by its expanded marketing and sales initiatives. Solid product sales growth of 26% during Q1 2016 along with a significantly improved balance sheet has positioned PBI for this anticipated rapid growth. The Company continues to meet or exceed its publicly-disclosed goals, and continues to give guidance that it anticipates an up-listing to a major exchange in 2016. We believe PBIO can soon surpass its 52- week high in share price.



| Income Statement | FY 2014 | FY 2015 | 3/31/16 | Balance Sheet | FY 2014 | FY 2015 | 3/31/16 | Cash Flow Statement | FY 2014 | FY 2015 | 3/31/16 |
|---|-------------|-------------|-------------|----------------------------|-------------|-------------|--------------|-----------------------|-------------|-------------|-------------|
| Revenue | 1,374,744 | 1,797,691 | 510,478 | Cash & cash equivalents | 473,948 | 116,783 | 93,387 | Operating Cash Flow | (3,210,578) | (3,819,746) | (1,233,458) |
| Gross Profit | 697,712 | 800,937 | 288,779 | Total Assets | 1,744,132 | 1,804,388 | 1,967,508 | Investing Cash Flow | (7,139) | (9,412) | - |
| Operating Loss | (3,338,350) | (3,565,182) | (1,045,945) | Total Liabilities | 3,803,863 | 9,782,036 | 15,828,583 | Financing Cash Flow | 3,660,248 | 3,471,993 | 1,210,062 |
| Net Loss | (4,612,540) | (7,415,298) | (5,950,391) | Total Shareholder's Equity | (2,059,731) | (7,977,648) | (13,861,075) | Cash at end of period | 473,948 | 116,783 | 93,387 |
| Figure 2: PBIO 1 Year Price Chart 5-22-16 Figure 3: PBIO 6 Month Price Chart 5-22-16 Figure 3: PBIO 6 Month Price Chart | | | | | | | | | | | |
| | , | | | | 0.60 | | 8 | | | | 0.60 |
| | | | | all | 0.55 | | | | | | 0.55 |
| | | | | | 0.50 | | | | n†A | dalar μ | |



Sector: Healthcare
Industry: Medical Devices &
Technology

Website: www.pressurebiosciences.com

Key Statistics

| Price 5/31/2016 | 0.48 | | | |
|------------------------|--------|--|--|--|
| 52 Week High | 0.58 | | | |
| 52 Week Low | 0.20 | | | |
| Avg. Vol (30day) | 78,967 | | | |
| Beta | 0.29 | | | |
| Market Cap (Interday) | 13.27M | | | |
| Insider Ownership (%) | 10.3% | | | |
| Shares Outstanding (M) | 23.21 | | | |
| Float (M) | 19.93 | | | |
| EPS(ttm) | -0.52 | | | |
| | | | | |

Source: Cap IQ/Google Finance

Recent 2016 Highlights

- May 18, 2016 PBI announced 26% product revenue growth for the first quarter, including strong instrument and consumable sales.
- April 12, 2016, PBI was added to the highperforming Richmond Club Index. The Richmond Index has outperformed the S&P 500 Index by an average of 11% each year for the past ten years.
- March 31, 2016, PBI closed an additional \$769K in PIPE financing. This final close brought the total working capital raised to over \$6.3M, substantially above Company's goal of \$5M. Proceeds were used to pay off all of its variable rate (floorless) convertible debt, eliminating the risks of substantial dilution. The new shares were issued at a conversion rate of \$.28 per share.
- March 14, 2016, PBI announced that it would participate in the SCIEX Workshop on New Innovations Towards Industrialized Proteomics at the US HUPO Conference (a major protein-related conference in the U.S.).
- October 2015, PBI announced a collaboration agreement with Florida International
 University to co-develop an improved rape
 kit test method, based on PBI's PCT platform, to aid in the testing of an estimated
 backlog of 200,000 400,000 untested rape
 kits.

Corporate Contact Information

Pressure BioSciences Inc. Richard T. Schumacher, CEO 14 Norfolk Ave. South Easton MA, 02375 Phone: 508-230-1828 www.pressurebiosciences.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$3500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.